Approval / Acknowledgement Letter Ref No. / Diary no F.No.12-48/GSK/PAC- Synflorix/15-BD 25-Mar-15 2 GlaxoSmithKline Pharmaceuticals Limited.
|
|
- Beverly Long
- 6 years ago
- Views:
Transcription
1 1 GlaxoSmithKline Deletion of a n-significant in-process test limit during the purification process of the tetanus / diphtheria toxoids used in the manufacture of GSK's PCV vaccine [brand name: Synflorix] F /GSK/PAC- Synflorix/15-BD 25-Mar-15 2 GlaxoSmithKline Application for a Post Approval Change in Biological Product - To reclassify fill volume controls from in-process control to process parameter/measurements with alert and action levels performed during the filling process of GSK's MMRV vaccine - Measles, mumps, rubella and varicella vaccine (live) Ph. Eur. F /GSK/PAC- MMRV/15-BD 25-Mar-15 3 GlaxoSmithKline 4 GlaxoSmithKline 5 GlaxoSmithKline Asia Private Application for a Post Approval Change in Biological Product - Introduction of a mir to the Quality Control (QC) procedures for the final container volume determination and update to the final target fill volume controls for the diluent Water for Injection used for GSK's MMRV vaccine - Measles, mumps, rubella and varicella vaccine (live) Ph. Eur. I Addition of Tuas-Singapore site for manufacturing and QC testing of adsorbed movalent conjugate bulk for the 10th serotype (PS-5) used in GSK s Pneumococcal Polysaccharide Conjugate Vaccine (adsorbed) Ph. Eur.] [Brand Name: Synflorix] tification of a Post Approval Change in Biological Product - Deletion of a n-significant in-process test limit during the purification process of the tetanus toxoids used in the manufacture of GSK's Haemophilus Type b conjugated vaccine - Hib Vaccine (Brand Name: HIBERIX) F. NO /GSK/PAC- MMRV/15-BD 26-Mar-15 F /GSK/PAC- Synflorix/15-BD 28-Apr-15 F /GSK/PAC- Hibrix /15-BD 26-Jun-15
2 6 GlaxoSmithKline tification of Level Post Approval Changes for GSK's HBV vaccine - Hepatitis B Virus (rdna) Vaccine IP [Engerix B Paediatric/ Adult] - Correction of the compendial references to the analytical methods mentioned in the registration dossier 1. The purity by Sodium Dodecyl Sulphate Drug Substance: HBsAg PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 2. The aluminium identity testing method for Aluminium Hydroxide gel or Al(OH)3 F /GSK/PAC- Rotarix/15-BD 01-Oct-15 7 GlaxoSmithKline Asia Private 8 GlaxoSmithKline Asia Private 9 GlaxoSmithKline tification of Post Approval Change (Level ) in Biological Product Reduction of PRN load on Q-Sepharose column Vaccines Impacted: - Diphtheria Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [Infanrix ] - Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, reduced antigens content) Ph. Eur. [Boostrix ] tification of a Post Approval Change for GSK's Human Rotavirus Vaccine (HRV) - Rotavirus Vaccine (Live Attenuated, Oral) IP [Brand Name: Rotarix] Change in the name of the diluent manufacturing site (intermediate site) from Glaxo Wellcome NDB to Aspen NDB tification of a Post Approval Change for GSK's MMRV Vaccine - Measles, Mumps, Rubella and Varicella vaccine (live) Ph. Eur. [Brand Name: Priorix Tetra] Change in the name of the diluent manufacturing site (intermediate site) from Glaxo Wellcome NDB to Aspen NDB DCGI Diary v-15 F /GSK/PAC- Rotarix/16-BD 18-Dec-15 DCGI Diary Dec-15
3 10 GlaxoSmithKline Asia Private 11 GlaxoSmithKline Asia Private 12 GlaxoSmithKline 13 GlaxoSmithKline & Correction of the compendial references to the analytical methods mentioned in the registration dossier -The assay and loss on drying tests of dipotassiumphoshate trihydrate -The sterility test by direct iculation -The formaldehyde content by spectrophotometry -The aluminium identity testing method for Aluminium Hydroxide gel or Al(OH)3 Vaccine impacted: Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, reduced antigens content) Ph. Eur. [BOOSTRIX] Application for Post Approval Change in Biological Product - Addition of an additional freeze-dryer at the registered Fidia manufacturing site (FIDIA Farmaceutici S.p.a., Padova, Italy) for the production of GSK's Measles, Mumps and Rubella Vaccine (live) IP [MMR] tification of a Post Approval Change in Biological Product - Addition of building SG05 for n-sterile further purification steps of the tetanus & diphtheria toxoids used as carrier protein in manufacture of GSK's pneumococcal conjugated vaccine [brand name: Synflorix] Application for the below post approval s 1. Use of building Wavre rd 30 (WN30) at the GSK biologicals, Wavre, Belgium site as an additional facility for formulation 2. Addition of alternative container for DP intermediate storage 1. Hepatitis A (Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [HAV-HAB] 2. Inactivated Hepatitis A Vaccine (Adsorbed) IP [HAV] F /GSK/PAC- Boostrix/15-BD 10-Jul-15 F /GSK/PAC- MMRV/15-BD 3-Aug-15 F /GSK/PAC- Synflorix/15-BD 17-Aug-15 F /GSK/PAC- Hep A&B/15-BD 1-Oct-15
4 14 GlaxoSmithKline 15 GlaxoSmithKline Asia Private Application for Post Approval Change in Biological Product - New reference standard for Hepatitis A antigen content by Enzyme Linked Immusorbent Assays (ELISA) and Potency hepatitis A antigen by ELISA assays performed as part of in process and QC release testing of the drug substance and during QC release testing Impacted vaccines: 1. Hepatitis A (Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [HAV-HAB] 2. Inactivated Hepatitis A Vaccine (Adsorbed) IP [HAV] Application for Post Approval Change in Biological Product Use of building Wavre rd 30 (WN30) at the GSK Biologicals, Wavre, Belgium site as an additional facility for formulation of Human Papillomavirus Vaccine rdna Ph. Eur. [CERVARIX] F /GSK/PAC- Hep.A/15-BD 26-Oct-15 F /GSK/PAC- Cervarix/ 15-BD dated 01-Dec Dec-15
5 16 GlaxoSmithKline 17 GlaxoSmithKline Asia Private Application of Post Approval Change in Biological Product Revision of the vial rubber stoppers release specifications for various lyophilized and liquid vaccines Vaccines Impacted: Pneumococcal Polysaccharide Conjugate Vaccine (adsorbed) Ph. Eur. [Synflorix ] Hepatitis A (Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [Twinrix Adult] Varicella Vaccine, Live IP [Varilrix ] Inactivated Hepatitis A Vaccine (Adsorbed) IP [Havrix 1440 (Adult)/720 (Junior)] Poliomyelitis Vaccine (Inactivated) IP [Poliorix] Hepatitis B Vaccine (rdna) IP (Genetically Engineered) [Engerix B 20 mcg/1 ml (Adult) / Engerix B 10 mcg/0.5 ml (Paediatric)] Measles, Mumps, Rubella and Varicella vaccine (Live) Ph. Eur. [Priorix Tetra] Application of Post Approval Change in Biological Product Revision of the vial rubber stoppers release specifications for various lyophilized and liquid vaccines Vaccines Impacted: - Human Papillomavirus Vaccine rdna Ph Eur. [Cervarix ] - Rotavirus Vaccine (Live Attenuated, Oral) IP [Rotarix ] - Diphtheria Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [Infanrix ] - Haemophilus type b conjugated vaccine IP [Hiberix ] - Meningococcal Polysaccharide Vaccine IP [Mencevax ACWY] - Measles, Mumps and Rubella Vaccine (live) IP [Priorix ] - Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, reduced antigens content) Ph. Eur. F /GSK/PAC- Many Vaccines/15-BD 09-Sep-15 F /GSK/PAC- Many Vaccines/15-BD 09-Sep-15
6 [Boostrix ] 18 GlaxoSmithKline Asia Private 19 GlaxoSmithKline Asia Private 20 GlaxoSmithKline Asia Private & Application for approval of Post Approval Changes for GSK's HRV vaccine - Rotavirus Vaccine (Live Attenuated, Oral) IP [ROTARIX] - Correction of the compendial references to the analytical methods mentioned in the registration dossier 1. The sterility test Mycoplasma by culture 2. The assay and loss on drying tests of dipotassium phosphate trihydrate Application for Level Post Approval Change - Change in the retest period (or shelf-life) for the drug substance, involving: Extension of Shelf life of Diphtheria Tetanus (DT) concentrate from 24 months to 36 months Impacted GSK vaccines: Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, reduced antigens content) (dtpa) [Brand Name: BoostrixJ Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) (DTPa) [Brand Name: lnfanrix] Correction of the compendial references to the analytical methods mentioned in the registration dossier -The assay and loss on drying tests of dipotassiumphoshate trihydrate -The sterility test by direct iculation -The formaldehyde content by spectrophotometry -The aluminium identity testing method for Aluminium Hydroxide gel or Al(OH)3 Vaccine impacted: Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [INFANRIX] F /GSK/PAC- Rotarix/15-BD. 12-Feb-16 F /GSK/PAC- DT/15-BD 12-Feb-16 F /GSK/PAC- Infanrix/16-BD 16-Feb-16
7 21 GlaxoSmithKline Asia Private 22 GlaxoSmithKline 23 GlaxoSmithKline Asia Private Application for Post Approval Change in Biological Products - Replacement of dtpa reference vaccine used in mouse immugenicity assay for Acellular pertussis (Pa) antigens for GSK's dtpa vaccine - Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [Brand Name: BOOSTRIXJ tification of Level Post-approval : Decommission of packaging and labeling activities in Pre-filled Syringes in Building DR A/B located in Dresden, Germany 1. Hepatitis A Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [Twinrix Adult] 2. Inactivated Hepatitis A Vaccine (Adsorbed) IP [Havrix Adult/Pediatric] Application for Post-Approval Change (Level ) in Biological Product - Change in the specification of raw material addition of a test of the foam breaking function of the antifoam emulsion used as a raw material 1. Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [lnfanrix] 2. Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, Reduced Antigens content) Ph. Eur. [Boostrix] F /GSK/PACdTpa/16-BD 19-Feb-16 F /GSK/PAC- MV /16-BD 8-Mar-16 F /GSK/PAC- Boostrix & Infanrix/ 16- BD 8-Mar-16
8 24 GlaxoSmithKline Asia Private 25 GlaxoSmithKline 26 GlaxoSmithKline Asia Private & Application for Post Approval Change in Biological Product Correction of the compendial references to the analytical methods mentioned in the registration dossier for GSK s HPV vaccine [brand name: Cervarix] 1. Sterility test Mycoplasma by culture 2. Purity by SDS-PAGE 3. Aluminium identity test for Al(OH)3 gel 4. Protein content by total nitrogen assay tification of Level Ill Post Approval Changes for GSK's HAB vaccine- Hepatitis A (Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [Twinrix Adult] Introduction of the sterility tests by membrane filtration as Quality Control (QC) release test on adsorbed Hepatitis A antigen (ADFIHA) intermediate final bulk Introduction of the sterility tests by membrane filtration as Quality Control (QC) release test on adsorbed Hepatitis B antigen (HBsAg) concentrate (AHEF) intermediate final bulk Application for Post-Approval Change in Biological Product - Increase in the lifetime of the TFF membrane filter used in the manufacture of MPL powder, an excipient used in GSK s HPV Vaccine [brand name: Cervarix] F /GSK/PAC- HPV/16-BD dated 08- Mar Mar-16 F /GSK/PAC- HAB vaccine/16-bd 8-Mar-16 F /PAC- Cervarix/16-BD dated 08-Mar Mar-16
9 27 GlaxoSmithKline Asia Private 28 GlaxoSmithKline 29 GlaxoSmithKline I & tification of Level Post-approval : Decommission of packaging and labeling activities in Pre-filled Syringes in Building DR A/B located in Dresden, Germany 1. Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [lnfanrix] 2. Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, Reduced Antigens content) Ph. Eur. [Boostrix] Application for Post-Approval Changes (Level I & Level ) in Biological Product - Scale up of microfluidised PS5 and PS19F bulks and shelf-life extension of microfluidised PS5 used in the manufacture of GSK s pneumococcal vaccine (Synflorix) & Application for Post Approval Changes in Biological Product Correction of the compendial references to the analytical methods used in the testing of raw material for DS and DS intermediate for GSK s pneumococcal polysaccharide conjugate vaccine [brand name: Synflorix] -Dipotassium phosphate trihydrate (K2PO4.3H2O) -Purified Tetanus Toxoid (TT) bulk DCGI Diary Mar-16 F /GSK/PAC- Synflorix/ 16-BD 8-Apr-16 F /GSK/PAC- Synflorix/ 16-BD 8-Apr GlaxoSmithKline & Application for approval of Post Approval Changes for GSK's HAV vaccine - Inactivated Hepatitis A Vaccine (Adsorbed) IP (HAVRIX) - Correction of the compendial references to the analytical methods mentioned in the registration dossier 1. The sterility test Mycoplasma by culture 2. The aluminum identity testing method for Aluminum Hydroxide gel or Al(OH)3 3. The determination of formaldehyde content by spectrophotometry F /GSK/PAC- HAV/16-BD 11-Apr-16
10 31 GlaxoSmithKline Asia Private 32 GlaxoSmithKline 33 GlaxoSmithKline tification of a Level Ill Post Approval Change for Suppression of formulation, filling and lyophilization activities in RX.16.1 site for Vials in Rixensart, Belgium 1. Rotavirus Vaccine (Live Attenuated, Oral) IP [Rotarix] tification of a Level Ill Post Approval Change for Suppression of formulation, filling and lyophilization activities in RX.16.1 site for Vials in Rixensart, Belgium 1. Inactivated Hepatitis A Vaccine (Adsorbed) IP [Havrix Adult/Pediatric] 2. Poliomyelitis Vaccine (Inactivated) IP [Poliorix] & Application for Post Approval Changes in Biological Product - Change in description test and introduction of nephelometry on Hepatitis B surface antigen (HBsAg) bulk of GSK's Hepatitis B containing vaccines. Impacted vaccines: 1. Hepatitis A (Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [HAV-HAB] 2. Hepatitis B Virus (rdna) Vaccine IP [HBV] F /GSK/PAC- Rotavirus/16-BD 18-Apr-16 F /GSK/PAC- Hep-A, Polio/16-BD 18-Apr-16 F /GSK/PAC- Hepatitis/16-BD 25-Apr GlaxoSmithKline Asia Private (requiring CDL review) Application for Level Post-Approval Change Change in the re test period (or shelf Life) for the drug substance, involving: Extension of Shelf Life of PRN bulk from 24 months to 36 months. Impacted Vaccines: Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, Reduced Antigen Content) Ph. Eur. [Brand Name: BOOSTRIX] Diphtheria, Tetanus and Pertussis (Acellular Component) F /GSK/PAC - MV/16-BD 4-May-16
11 Vaccine (Adsorbed) Ph. Eur. [INFANRIX] 35 GlaxoSmithKline Asia Private Replacement of the current in-house working reference serum (WRS) used in the in vitro part of the potency assay (one-dose test) for the acellular Pertussis (Pa) components of Pa-containing vaccines Impacted Vaccines: Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, Reduced Antigen Content) Ph. Eur. [Brand Name: BOOSTRIX] Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [INFANRIX] F /GSK/PAC- Boostrix & Infanrix / 16- BD 4-May GlaxoSmithKline 37 GlaxoSmithKline Asia Private (requiring CDL review) Application for Post-Approval Change (Level ) in Biological Product Extension of shelf-life for GSK s pneumococcal polysaccharide conjugate vaccine (Synflorix) in Pre-Filled Syringe from 36 to 48months. tification of Post Approval Change (Level ) in Biological Product Introduction of the sterility test by membrane filtration as QC release test on ATTOAA intermediate used in the formulation of GSK s dtpa vaccine [brand name: Boostrix] F /GSK/PAC- Synflorix/ 16-BD 4-May-16 F /GSK/PAC- Boostrix/16-BD 13-May-16
12 38 GlaxoSmithKline & Application for Post-Approval Changes (Level and Level ) in Biological Product Removal of compendial references for analytical procedures o Sterility test Mycoplasma detection by culture method o Neomycin sulphate content by radial diffusion o Particle count test for diluent (WFI) Impacted vaccines: Measles, Mumps, Rubella and Varicella vaccine (Live) Ph. Eur. [Priorix Tetra] Varicella Vaccine, Live IP [Varilrix ] F /GSK/PAC- MMRV vaccine/ 16-BD 24-May GlaxoSmithKline Asia Private 40 GlaxoSmithKline 41 GlaxoSmithKline Asia Private & Application for Post-Approval Changes (Level and Level ) in Biological Product Removal of compendial references for analytical procedures used in GSK s MMR vaccine [brand name: Priorix] o Sterility test Mycoplasma detection by culture method o Neomycin sulphate content by radial diffusion o Particle count test for diluent (WFI) : tification of Post-Approval Change (Level ) in Biological Product - modification in the ph target and range used at the final ph adjustment during preparation of purified TT bulk, a carrier protein used in GSK s Pneumococcal Polysaccharide Conjugate Vaccine (adsorbed) Ph. Eur. [brand name: SYNFLORIX] tification of Post-Approval Change (Level ) in Biological Product Introduction of BioReliance, Rockville, MD, USA as additional QC site responsible to conduct the Rabbit Pyrogen assay test for MPL powder, an excipient used in GSK s HPV vaccine [brand name: Cervarix] F /GSK/PAC- MMR vaccine/16-bd 24-May-16 F /GSK/PAC- Synflorix/16-BD 3-Jun-16 F /GSK/PAC- HPV /136-BD 15-Jun-16
13 42 GlaxoSmithKline Asia Private 43 GlaxoSmithKline 44 GlaxoSmithKline Application for Post-Approval Change (Level ) in Biological Product Change of source of raw material cystine for Tetanus - Marburg 1. Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [lnfanrix) 2. Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, Reduced Antigens content) Ph. Eur. [Boostrix) Application for Approval of a Level Post-Approval Change - Introduction of Maximum Storage Period for Hepatitis A (HAV) Iculum 1. Hepatitis A (Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [Twinrix Adult] 2. Inactivated Hepatitis A Vaccine (Adsorbed) IP [Havrix Adult/Pediatric] & Application for approval of Post Approval Changes for GSK's HAB vaccine - Hepatitis A (Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [Twinrix Adult] - Correction of the compendia} references to the analytical methods mentioned in the registration dossier 1. The sterility test Mycoplasma by culture 2. The purity by Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 3. The aluminum identity testing method for Aluminum Hydroxide gel or Al(OH)3 4. The determination of formaldehyde content by Spectrophotometry F /GSK/PAC- Boostrix & Infanrix/ 16- BD 27-Jun-16 F /GSK/PAC- Twinrix & Havrix/16-BD 8-Aug-16 F /GSK/PAC- HAV & HBV/ 16-BD 8-Aug-16
14 45 GlaxoSmithKline 46 GlaxoSmithKline 47 GlaxoSmithKline 48 GlaxoSmithKline 49 GlaxoSmithKline (requiring CDL review), but seeking approval and Application for Approval of a Level Post-Approval Change for correction of Compendial References to the Analytical methods mentioned in the Registration Dossier for GSK's HBV Containing Vaccines. Vaccine impacted: Hepatitis A Inactivated) and Hepatitis B (rdna) Vaccine (Adsorbed) IP [Twinrix Adult] Application for approval of Post-Approval Changes in Biological Product for GSK's Varicella vaccine [brand name: Varilrix] 1) Alignment of Varilrix table of composition in line with source country (Belgian) approval 2) Inclusion of the reference to Ph. Eur. mograph 0806 for Arginine Application for Post-Approval Change (Level ) in Biological Product Introduction of a shelf-life of 96 months at -196 C for the Varicella iculum used in the manufacturing process of GSK s MMRV and Varicella vaccines based on available stability data Vaccines Impacted: - MMRV vaccine [brand name: PRIORIX-TETRA] - Varicella vaccine [brand name: VARILRIX] Application for Post-Approval Changes (Level and Level ) in Biological Product - Change of specification for the antigenic activity performed at release and during stability evaluation of HBV bulk, a drug substance of GSK s HAB vaccine [brand name: TWINRIX ADULT] Application for Post-Approval Changes (Level ) Update to the description of QC release tests (Identity and Potency) performed during the manufacture of the rubella virus live attenuated bulk (DS) and on the final container (DP) F /GSK/PAC- Twinrix/16-BD 30-Aug-16 F /GSK/PAC- Varilrix/16-BD 30-Aug-16 F /GSK/PAC- MMRV & Varicella/ 16- BD 30-Aug-16 F /GSK/PAC- HAB/ 16-BD 22-Sep-16 F /GSK/PAC- MMRV I 16-BD 26-Sep-16
15 Vaccine Impacted: MMRV vaccine [brand name: PRIORIX-TETRA] 50 GlaxoSmithKline Asia Private 51 GlaxoSmithKline 52 GlaxoSmithKline Asia Private (requiring CDL review), category according to the guidance, category according to the guidance Application for Post-Approval Changes (Level ) Update to the description of QC release tests (Identity and Potency) performed during the manufacture of the rubella virus live attenuated bulk (DS) and on the final container (DP) Vaccine Impacted: MMR vaccine [brand name: PRIORIX] Application for Post Approval Changes (Level ) in Biological Product Update to the description within the registration files for internal controls, solutions and media Impacted vaccines: - Measles, Mumps, Rubella and Varicella Vaccine (Live) Ph. Eur. [Priorix-Tetra] - Varicella Vaccine, Live IP [Varilrix] Application for Post Approval Changes (Level ) in Biological Product Update to the description within the registration files for internal controls, solutions and media Impacted vaccine: - Measles, Mumps & Rubella Vaccine (Live) IP [Priorix] F /GSK/PAC- MMR/16-BD 26-Sep-16 F /GSK/PAC- MMRV & Varicella /16- BD 26-Sep-16 F /GSK/PAC- MMR/16-BD 26-Sep-16
16 53 GlaxoSmithKline Asia Private 54 GlaxoSmithKline Asia Private Application for Post-Approval Change (Level ) in Biological Product - Replacement of the current Pertactin (PRN) Reference Standard by a new proposed batch 1. Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed, reduced antigens content) Ph. Eur. [brand name: BOOSTRIX] 2. Diphtheria, Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. [brand name: INFANRIX] tification of a Level Post Approval Change in Biological Product- Tightening of Temperature Criterion of Diluent Used in GSK's Rotavirus Vaccine (Live Attenuated, Oral) IP [Rotatix]. F. / 12-64/GSK/PAC- Boostrix&Infanrix/16- BD 9-Dec-16 DCGI Diary Dec GlaxoSmithKline 56 GlaxoSmithKline Application for Approval of a Level Post Approval Change in Biological Products - Revision of Glass Vial Container Release Specifications for all Vaccine Formulations Filled in Glass Vial Containers. 1. Inactivated Hepatitis A Vaccine (Adsorbed) IP [Havrix 1440 (Adult)/720 (Junior)] 2. Poliomyelitis Vaccine (Inactivated) IP [Poliorix] 3. Measles, Mumps, Rubella and Varicella Vaccine (Live) Ph. Eur. [Priorix-Tetra] 4. Pneumococcal Polysaccharide Conjugate Vaccine (Adosrbed) Ph. Eur. [Synflorix] 5. Varicella Vaccine, Live IP [Varilrix] tification of Post Approval Change (Level ) in Biological Product Use of a new working seed of Streptococcus pneumoniae serotype 18C used to produce PS18C bulks, an intermediate in the production of GSK s pneumococcal vaccine (SYNFLORIX) F /GSK/PAC- Many vaccines/16-bd 21-Dec-16 DCGI Diary Dec-16
17 57 GlaxoSmithKline 58 GlaxoSmithKline Asia Private Application for Post-Approval Change (Level ) in Biological Product Extension of shelf-life for GSK s pneumococcal polysaccharide conjugate vaccine [SYNFLORIX] in 1-dose and 2- dose Vial from 36 to 48months Application for Approval of a Level Post Approval Change in Biological Products - Revision of Glass Vial Container Release Specifications for all Vaccine Formulations Filled in Glass Vial Containers. 1. Human Papillomavirus Vaccine rdna Ph. Eur. [Cervarix] 2. Measles, Mumps and Rubella Vaccine (Live) [Priorix] 3. Rotavirus Vaccine (Live Attenuated,-Oral) LP. [Rotarix] F / GSK/PAC- Synflorix/ 16-BD 28-Dec-16 F /GSK/PAC- Many vac/16-bd 9-Jan-17
Advisory Committee on Immunization Practices VACCINE ACRONYMS
Vaccine Acronyms Page 1 of 5 Advisy Committee on Immunization Practices VACCINE ACRONYMS Vaccines Included in the Immunization Schedules f Children, Adolescents, and Adults Following is a table of standardized
More informationNew Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines
New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines Antigens Vaccine Approved Age Daptacel Diphtheria, Tetanus, and acellular Pertussis (DTaP)
More informationTRICARE Retail Vaccination Program Vaccine List - September 2018*
Diphtheria, tetanus and pertussis Diphtheria and tetanus toxoids adsorbed acellular pertussis adsorbed DT DTaP Diphtheria and tetanus toxoids adsorbed Daptacel, Infanrix Tetanus and diphtheria toxoids
More informationChanges to the National Immunisation Schedule
17 December 2013 Changes to the National Immunisation Schedule PHARMAC is pleased to announce decisions related to the National Immunisation Schedule (NIS) that will take effect from 1 July 2014. This
More informationBharat Biotech. Hyderabad. Type of PAC (Supplement and Notifiable / Permission Granted by CDSCO) S. No Product
Bharat Biotech Hyderabad S. No Product Type of PAC (Supplement and / Permission Granted by CDSCO) PAC Details Date of NOC in manufacturing process of Oral Polio F.No. 12-63/BHARAT/(PACOPV)/13-BD 30.08.2013
More informationAdvisory Committee on Immunization Practices VACCINE ACRONYMS
May 1, 2015 Vaccine Acronyms Page 1 of 5 Advisy Committee on Immunization Practices VACCINE ACRONYMS Vaccines Included in the Immunization Schedules f Children, Adolescents, and Adults Following is a table
More informationPREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.
An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationPREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.
An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation
More informationGENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES
GENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES DTaP: Diphtheria, Tetanus, acellular Pertussis Vaccine Infanrix Licensed in 1997
More informationSTANWOOD-CAMANO SCHOOL DISTRICT REQUEST FOR PART-TIME ATTENDANCE OR ANCILLARY SERVICES FROM PRIVATE SCHOOL PUPIL
STANWOOD-CAMANO SCHOOL DISTRICT REQUEST FOR PART-TIME ATTENDANCE OR ANCILLARY SERVICES FROM PRIVATE SCHOOL PUPIL 114 F2 Students Please complete ALL information: Name of Pupil Grade Address of Pupil City
More informationVaccine Label Examples
Vaccine Label Examples With the large amount of vaccine carried in most clinics, staff can easily become confused about vaccines within the storage unit. Labeling the area where vaccines are stored can
More informationVACCINE MANAGEMENT. Recommendations for Handling and Storage of Selected Biologicals. January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES
VACCINE MANAGEMENT Recommendations for Handling and Storage of Selected Biologicals January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES DTaP: Diphtheria Toxoid, Tetanus Toxoid, Acellular Pertussis Vaccine
More informationVaccine Label Examples
Vaccine Label Examples With the large amount of vaccine carried in most clinics, staff can easily become confused about vaccines within the storage unit. Labeling the area where vaccines are stored can
More informationVaccination Decision Making: What Providers Need to Know
Objectives Vaccination Decision Making: What Providers Need to Know Kelli Smith, RN, BSN Iowa Department of Public Health Immunization Program Catch-up Schedule: how to most efficiently bring persons up-to-date
More informationHexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines
Viral Hepatitis Prevention Board Hanoi, 25 26 July 2018 Hexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines Prof. Timo Vesikari Vaccine Research Center University
More informationDetailed cost of vaccination/ Immunization in India (Birth to 10 years of age)
Detailed cost of vaccination/ Immunization in India (Birth to 10 years of age) Glossary: IPV= Injectable Polio vaccine OPV= Oral polio vaccine (these are oral drops, which is also given in "Pulse Polio
More informationI certify that the information provided on this form is correct and verifiable. Month Day Year
Certificate of Immunization Status (CIS) DOH 48-0 January 05 Please print. See back for instructions on how to fill out this form or get it printed from the Immunization Information System. Child s Last
More informationVaccinology 101 for Fellows
Vaccinology 101 for Fellows Meg Fisher, MD Medical Director, The Children s Hospital Monmouth Medical Center An affiliate of the Saint Barnabas Health Care System Long Branch, NJ Disclosures I have no
More informationVictorian immunisation catch-up tool for 10 to 19 year olds
Victorian immunisation catch-up tool for 10 to 19 year olds For healthy children with no documented history of vaccine administration The objective of catch-up vaccination is to complete a course of age
More informationCoverage of Vaccines Medicaid and Child Health Plus Members
Coverage of Vaccines Medicaid and Child Health Plus Members For children between the ages 0-18, routine recommended vaccinations are covered through Vaccines for Children program [VFC]. Fidelis Care will
More informationTemperature Intelligence Solutions. Thermostability of Vaccines
Thermostability of Vaccines Why are all vaccines sensitive to heat and some to freezing? Why is thermostability of vaccine important? What can be done to improve the thermostability of vaccines? Goals
More informationModern Drug House.
+91-8048941768 Modern Drug House https://www.moderndrughouse.in/ We are one of the leading suppliers and traders of a wide range of Vaccine and Pharmaceutical Products. Owing to its effectiveness, purity
More informationEARLY CHILDHOOD DEVELOPMENT & EDUCATION
A division of Pawsitively Bassett, Inc. EARLY CHILDHOOD DEVELOPMENT & EDUCATION 08-09 67 N. Monroe St., Spokane WA 9908 www.nlcpreschool.com (509) 8-00 Dear Parents, Thank you, for your interest in the
More informationSyrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation
Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,
More informationimmunisation in New Zealand
This appendix details the history of. Section A1.1 is a brief summary of when each vaccine was introduced to the National Immunisation Schedule (the Schedule). This summary includes vaccines which were
More informationBabyJabs Vaccines. All vaccines are mercury- free We use aluminium- free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury- free We use aluminium- free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAll Kindergarteners and 4-6 year old transfer students. 4 doses DTP or DTaP 1 dose must be at or after 4 years of age. None
Parents Vaccines Required for School Entry in Michigan Whenever children are brought into group settings, there is a chance for diseases to spread. Children must follow state vaccine laws in order to attend
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationBabyJabs Vaccines. All vaccines are mercury-free We use aluminium-free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury-free We use aluminium-free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory INFANRIX HEXA Diphtheria, tetanus, pertussis (acellular component), hepatitis B (rdna), poliomyelitis (inactivated) and
More informationBabyJabs Vaccines. All vaccines are mercury-free We use aluminium-free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury-free We use aluminium-free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationObjectives. Immunity. Childhood Immunization Risk of Non-Vaccinated Children 12/22/2015
Childhood Immunization Risk of Non-Vaccinated Children Bertha P. Rojas, Pharm.D. PGY-1 Pharmacy Resident South Miami Hospital Objectives Understand the definition of herd immunity Identify vaccine-preventable
More informationNational Immunisation News
July 2015 National Immunisation News The newsletter of the HSE National Immunisation Office CONTENTS Changes to the Primary Childhood Immunisation Programme BCG Shortage Pertussis Vaccine Mumps Order Vaccines
More informationImmunization Guidelines For the Use of State Supplied Vaccine July 1, 2011
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationVictorian immunisation catch-up tool for 10 to 19 year olds
Victorian immunisation catch-up tool for 10 to 19 year olds January 2018 Guidelines for 10 to 19 year olds with no documented history of vaccine administration The objective of catch-up vaccination is
More informationVaccine ingredients. Fact sheet August 2017 page 1. Continued...
Vaccine manufacture and composition is complex and tightly regulated to maximise safety. The safety of the individual components, and of the vaccine itself, must be demonstrated before a vaccine can be
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component)
More informationAppendix An Assessment Tool to Determine the Validity of Vaccine Doses
Appendix 4.4 - An Assessment Tool to Determine the Validity of Vaccine Doses Note: Refer to the Canadian Immunization Guide and New Brunswick (NB) immunization program directives for recommendations for
More informationImmunise your child on time. It s their best protection
Immunise your child on time It s their best protection If you are a parent or caregiver, this pamphlet is for you. It tells you about the recommended ages for your baby to receive their immunisations.
More informationA Review of Pediatric Vaccines Gary Overturf, M.D. Professor of Pediatrics, Inf. Dis. University of New Mexico
Review of Pediatric and Adolescent Vaccines 2012 Idaho Society of Health- System Pharmacists Boise, ID April 28 th 2012 A Review of Pediatric Vaccines - 2012 Gary Overturf, M.D. Professor of Pediatrics,
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET HIBERIX Haemophilus influenzae type b (Hib) powder and diluent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose
More informationNational Immunisation News The newsletter of the HSE National Immunisation Office
February 2015 National Immunisation News The newsletter of the HSE National Immunisation Office CONTENTS Changes to the PCI programme Uptake statistics Pneumovax name change Flu season Common queries School
More informationVaccines and other immunological antimicrobial therapy 1
Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that
More informationCHILDHOOD VACCINATION
EPI (3) Age of Child How and Where is it given? CHILDHOOD VACCINATION Nicolette du Plessis Block 10 28/02/2012 10 weeks DTaP-IPV/Hib (2) Diphtheria, Tetanus, Acellular pertussis, Inactivated polio vaccine,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChildhood Immunisations Template Guide 2017
Childhood Immunisations Template Guide 2017 1 Template Control Page Childhood Immunisations Template Guide Title Childhood Immunisations Author CEG Description Supports the schedule of Childhood Immunisations
More informationPractical Applications of Immunology. Chapter 18
Practical Applications of Immunology Chapter 18 I. Vaccines A. Definition A suspension of organisms or fractions of organisms that is used to induce immunity (immunologic memory). The mechanism of memory
More informationNational Immunisation News
National Immunisation News The newsletter of the HSE National Immunisation Office July 2016 Changes to the Primary Childhood Immunisation Programme The National Immunisation Advisory Committee (NIAC) has
More informationManitoba Annual Immunization Surveillance Report
Annual Immunization Surveillance Report January 1 to December 31, 2014 Epidemiology & Surveillance Public Branch Public and Primary Care Division, y Living and Seniors Released: January 2016 TABLE OF CONTENTS
More informationImmunisation Policy. Country Children s Early Learning Ph: M:
Immunisation Policy Published June 2018 Review Date December 2019 Sources Education and Care Services National Regulations, October 2017 Guide to the Education and Care Services National Law and the Education
More informationChildhood Immunisations Template Guide 2016
Childhood Immunisations Template Guide 2016 1 Template Control Page Childhood Immunisations Template Guide Title Childhood Immunisations Author CEG Version 9 Description Supports the schedule of Childhood
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component)
More informationEarly Learning Centre Immunisation Policy Legislation ACT Public Health Regulations (2000)
Early Learning Centre Immunisation Policy Legislation ACT Public Health Regulations (2000) National Quality Standard / Education and Care Services National Regulations Standard 2.1 Each child s health
More informationCenters for Disease Control and Prevention. Final Revised Vaccine Information Materials for MMR
This document is scheduled to be published in the Federal Register on 03/15/2018 and available online at https://federalregister.gov/d/2018-05299, and on FDsys.gov BILLING CODE: 4163-18-P DEPARTMENT OF
More informationSynflorix. Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed
Synflorix Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml) contains 1 microgram
More informationArmed Services Blood Program Immunization List
Immunization List NOTICE: The Department of Defense (DoD) assumes no risk for the use of this information by non-dod personnel, blood programs, or individual medical institutions. The use of this information
More information14: Immunological products and vaccines
File name: Immunological Products and s Formulary BNF Original Date of issue: 30/10/2005 Last Reviewed: 23/11/2012 Version:4 Page 1 of 6 14: Immunological products and vaccines 14.1 Active immunity Live
More informationImmunization Guidelines for the Use of State Supplied Vaccine May 17, 2015
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More information7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids
7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids Contents Introduction Nunavut Recommended Childhood Immunization Schedule Nunavut Routine Adult Immunization Schedule Nunavut Immunization
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX Haemophilus type b conjugated vaccine IP 1. NAME OF THE MEDICINAL PRODUCT Haemophilus type b conjugated vaccine
More informationVaccines, Not Just for Babies
Vaccines, Not Just for Babies Meg Fisher, MD Medical Director Disclosures I have no relevant financial relationships with the manufacturers of any commercial products or commercial services discussed in
More informationDiphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib) Section 7: Biological Product Information Standard #: 07.211 Created
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component)
More informationEnhanced immunisation schedule Victoria
Children from March 2016 Age Disease Vaccine brand Birth Hepatitis B H-B-Vax-II Paediatric 2 months - from 6 weeks Diphtheria-tetanus-pertussis, poliomyelitis-hepatitis B- Reconstitute Site given Route
More informationAnnex 1. WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine
WHO related to the manufacture and quality control of biological substances used in medicine WHO are intended to provide guidance to those responsible for the production of biological substances as well
More informationSKAGIT VALLEY FAMILY YMCA
Central Preschool Registration 2019-2020 Child s First : MI: Last : Address: City: State: Zip Home Phone: ( ) Gender: Birth : Age: Child lives w/ Mother/Guardian: Cell Phone: ( ) Employer: Work Phone:
More informationCPT 2016 Code Changes
CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer
More informationImmunisation Subcommittee of PTAC Meeting held 28 October 2015
Immunisation Subcommittee of PTAC Meeting held 28 October 2015 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationChild Care Registration Form
Child Care Registration Form child entered care Child s name Last First Middle Name (Nickname) used Birthdate Street address City Zip code Child s parent/guardian name home phone # cell phone# child left
More informationYukon Immunization Program Manual ADMENDMENTS & ADDITIONS
2012 August Page 1 Manual ADMENDMENTS & ADDITIONS Number & 11-01 2011 June 09 11-02 2011 October 11 12-01 2012 Feb 9 Topic Additions to Yukon Immunization Program Manual Twinrix, Twinrix Junior, Menamune,
More informationCenters for Disease Control and Prevention. Proposed Revised Vaccine Information Materials for MMR
This document is scheduled to be published in the Federal Register on 10/18/2016 and available online at https://federalregister.gov/d/2016-25144, and on FDsys.gov BILLING CODE: 4163-18-P DEPARTMENT OF
More informationImmunisation schedule Victoria
Infants and children July 2018 Birth H-B-Vax-II Paediatric or Paediatric 2 months (from 6 weeks) and 4 months Diphtheria-tetanus-pertussis, poliomyelitis-hepatitis B- Haemophilus influenzae type b Anterolateral
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationState of Alaska Child Care & School Immunization Requirements Packet Revised 08/2010
State of Alaska Child Care & School Immunization Requirements Packet Revised 08/2010 ALASKA IMMUNIZATION PROGRAM (907) 269-8000 OR 1-888-430-4321 http://www.epi.hss.state.ak.us/id/immune.stm (This page
More informationChild Health and Disability Prevention (CHDP) Program Code Conversion
Child Health and Disability Prevention (CHDP) Program Code Conversion Health s All s are effective for dates of service on or after July 1, 2017. (Select s for laboratory-only providers with effective
More information- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPRODUCT MONOGRAPH NIMENRIX. Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine. Powder and diluent for solution for injection
PRODUCT MONOGRAPH Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine Powder and diluent for solution for injection Active Immunizing Agent Pfizer Canada Inc. 17,300 Trans-Canada Highway
More informationFor the use only of a Registered Medical Practitioner or a Hospital or a Laboratory SYNFLORIX
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory SYNFLORIX Pneumococcal Polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) Protein D Conjugate Vaccine, adsorbed
More informationThe Scientific Relevance of the ATT Today and from a historical Perspective
www.pei.de The Scientific Relevance of the ATT Today and from a historical Perspective Dr. Klaus Cussler EPAA International Workshop Towards global harmonization of 3Rs in biologicals 15-16 September 2015
More informationPATH Quick Reference Guide: Coding for Pediatric Health HEDIS Measures
PATH Quick Reference Guide: Coding for Pediatric Health HEDIS Measures This guide is designed to be a quick reference tool to help with medical coding of select Healthcare Effectiveness Data and Information
More informationTable of Contents. 1.0 INFANRIX hexa VACCINE...3
Table of Contents 1.0 INFANRIX hexa VACCINE...3 1.1 What is INFANRIX hexa vaccine?...3 1.2 When will INFANRIX hexa be introduced?...3 1.3 What is the difference between INFANRIX hexa and Pediacel?...3
More informationPentabio Vaccine (DTP-HB-Hib)
SUMMARY OF PRODUCT CHARACTERISTICS Product Name Pharmaceutical Form Strength Presentation : Pentabio : Suspension for injection : 1, 5 and 10 doses : Box of 10 vials @ 0.5 ml Box of 10 vials @ 2.5 ml Box
More information1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References...
1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References... 7 2 General Recommendations on Immunization Timing and Spacing of Vaccines...
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, 2014. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information Name of Manufacturer Prequalification Team WHO PUBLIC INSPECTION
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET Name of the Medicinal Product MENITORIX Haemophilus type b and Neisseria meningitidis group C conjugate vaccine Presentation MENITORIX is presented as a powder and diluent for reconstitution
More informationDATA SHEET PRIORIX-TETRA. Name of Medicinal Product
DATA SHEET Name of Medicinal Product PRIORIX-TETRA Live attenuated measles, mumps, rubella and varicella vaccine Presentation PRIORIX-TETRA is a sterile lyophilised mixed preparation of the attenuated
More informationK 6 th Express Billing Contract
2017-2018 K 6 th Express Billing Contract Child Information: First Middle Initial Last Parent/Guardian Information: First Middle Initial Last Address Phone Requested Start Will you be receiving state/other
More informationBenefit Interpretation
Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents
More informationK 6 th Express Billing Contract
05-06 K 6 th Express Billing Contract Child Information: First Middle Initial Last Parent/Guardian Information: First Middle Initial Last Address Phone Requested Start Will you be receiving state/other
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET INFANRIX HEXA Combined diphtheria-tetanus-acellular pertussis, hepatitis B, enhanced inactivated polio vaccine and Haemophilus influenzae type b powder and suspension
More informationUse of Infanrix -IPV+Hib in the infant primary immunisation schedule
Use of Infanrix -IPV+Hib in the infant primary immunisation schedule An update for registered healthcare practitioners July 2014 Quality Education for a Healthier Scotland 1 Acknowledgments Many thanks
More informationPHARMAC invites proposals for the supply of various vaccines in New Zealand.
15 February 2016 Dear Supplier REQUEST FOR PROPOSALS SUPPLY OF VARIOUS VACCINES PHARMAC invites proposals for the supply of various vaccines in New Zealand. This request for proposals (RFP) letter incorporates
More information